Found 19 Dementia trials
A listing of Dementia medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Featured study
The purpose of this study is to evaluate memory, language and cognitive difficulties in patients with AD. AD is a neurological disease where a specific part of the brain is not functioning well. A clinical diagnosis of AD needs to be confirmed in all participants prior to participation in the …
Featured study
The purpose of this research study is to develop a better understanding of the genetic causes for frontotemporal degeneration (FTD), as well as Progressive Supranuclear Palsy (PSP) and Multiple System Atrophy (MSA). These conditions include difficulty with language and speaking, organization and planning, memory, and/or a behavior or personality change. …
Since its launch in 2004, the overarching aim of the Alzheimer’s Disease Neuroimaging Initiative (ADNI) has been realized in informing the design of therapeutic trials in AD. ADNI3 continues the previously funded ADNI1, ADNI-GO, and ADNI2 studies that have been combined public/private collaborations between academia and industry to determine the …
This is a double blind, randomized, placebo controlled trial in subjects with mild cognitive impairment or dementia due to Alzheimer's disease (AD). AMX0035 is a combination of two compounds, Sodium Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA) that are hypothesized to prevent neuronal death through distinct pathways. AMX0035 is not approved …
Cognition Therapeutics is developing an oral formulation of CT1812 to treat AD and mild cognitive impairment. This is a multi-center, Phase 1b, randomized, double-blind, placebo-controlled parallel-group trial in adults with mild to moderate AD, sponsored by the NIH. The primary purpose of this study is to evaluate target engagement of …
The purpose of this clinical trial is to test different strengths of a new trial medication, delgocitinib cream 1, 3, 8, and 20 mg/g, and to investigate how treatment with delgocitinib cream affects atopic dermatitis (a type of eczema). key eligibility include: Age 18 years and above. Diagnosis of AD …
The research study is being conducted to test the safety and tolerability (i.e., possible side effects) of an investigational drug called AL001 and to find out what effects AL001 has on the body. This is for people who have a confirmed progranulin gene mutation that causes frontotemporal dementia (FTD). Study …
The Longitudinal Early-onset Alzheimer's Disease Study (LEADS) is a non-randomized, natural history, non-treatment study designed to look at disease progression in individuals with early onset cognitive impairment . Clinical/cognitive, imaging, biomarker, and genetic characteristics will be assessed across three cohorts: (1) early onset Alzheimer's Disease (EOAD) participants, (2) early onset …
The study is at the Penn Memory Center at the University of Pennsylvania and is under the direction of David Wolk, M.D.. We are currently recruiting normal control participants ages 75 years and older. The purpose of this study is to collect, store and analyze cognitive data and biological samples, …
The study will enroll cognitively unimpaired individuals who are between the ages of 60-75 years with at least one APOE4 allele (HMs or HTs) and, if HTs, with evidence of elevated brain amyloid. Cognitively unimpaired subjects defined as having a Mini-Mental State Examination (MMSE) total score greater than or equal …
1 - 10 of 19
- 1
- 2
Please choose between Voice or SMS based delivery of verification code
or